Molineaux and Bradbury on board at Geron
This article was originally published in Scrip
Executive Summary
Geron has appointed Dr Susan Molineaux and Daniel Bradbury to its board of directors. Dr Molineaux is currently CEO and president of Calithera Biosciences which she co-founded in June 2010. Mr Bradbury previously served as CEO of Amylin Pharmaceuticals until its acquisition by Bristol-Myers Squibb in August 2012. He is currently on the boards of Illumina and Castle Biosciences.
You may also be interested in...
Almirall launches Constella in six European markets
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira raises $35m in series B
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis ups public offering to $240m
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.